Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential
biodata life science partner for rare and neurodegenerative
diseases, as part of a consortium of organizations in genetics,
announced the release of updated recommendations for Whole Genome
Sequencing (WGS) in the rare disease diagnostic setting. The
report, which was published in the European Journal of Human
Genetics, promotes standardized application of WGS – minimizing
diagnostic delay to promote better health outcomes.
The original guidelines for diagnostic Next Generation
Sequencing (NGS) were published in 2016 by EuroGentest, an
integrated working group within the European Society of Human
Genetics (ESHG), to support laboratories with the implementation
and execution of standardized diagnostics of rare diseases. At that
time, the guidelines predominantly focused on Whole Exome
Sequencing (WES) and gene panels to identify Single Nucleotide
Variants (SNVs) and insertions/deletions (indels).
Since then, WGS has been increasingly proven as an emerging and
comprehensive genetic testing technology to avoid diagnostic delay
and stepwise testing.
EuroGentest, Horizon2020’s Solve-RD team, CENTOGENE, and
organizations throughout Europe teamed up to evaluate and update
the 2016 NGS guidelines to outline the clinical application of WGS.
The recommendations are endorsed by the Solve-RD Steering
Committee, the representing European Reference Networks (ERNs), the
European Board of Medical Genetics (EBMG), and the ESHG.
Prof. Peter Bauer, Chief Genomic Officer at CENTOGENE, said, “As
a pioneer of rare disease diagnostics, we are committed to enabling
access to quality diagnostics and ensuring that leading-edge
insights are available to support better health outcomes. Whole
Genome Sequencing has been increasingly popular due to its advanced
nature of capturing disease-causing variants in a single test. We
are proud to have played a role in this initiative, which is a
perfect reflection of the significance of data, ongoing updates
that reflect the latest technology, and cross-institutional
collaboration to better serve physicians and patients.”
To read the recommendations for WGS in rare disease diagnostics,
visit: https://link.centogene.com/wgs-recommendations
About WGS at CENTOGENE
CentoGenome®, CENTOGENE’s WGS service, offers unparalleled
genome coverage and captures one of the most extensive ranges of
disease-causing genetic variants in a single test. Powered by the
CENTOGENE Biodatabank, the world’s largest real-world data
repository for rare and neurodegenerative diseases, CentoGenome has
the ability to solve up to 30% of WES negative cases.
To learn more about our advanced WGS solution, visit:
https://link.centogene.com/wgs-at-centogene
About CENTOGENE
CENTOGENE engages in diagnosis and research around rare diseases
transforming real-world clinical, genetic, and multiomic data to
diagnose, understand, and treat rare diseases. Our goal is to bring
rationality to treatment decisions and to accelerate the
development of new orphan drugs by using our extensive rare disease
knowledge and data. CENTOGENE has developed a global proprietary
rare disease platform based on our real-world data repository of
over 650,000 individuals representing over 120 different
countries.
The Company’s platform includes epidemiologic, phenotypic, and
genetic data that reflects a global population, as well as a
biobank of patients’ blood samples and cell cultures. CENTOGENE
believes this represents the only platform focused on comprehensive
analysis of multi-level data to improve the understanding of rare
hereditary diseases. It allows for better identification and
stratification of patients and their underlying diseases to enable
and accelerate discovery, development, and access to orphan drugs.
As of December 31, 2021, the Company collaborated with over 30
pharmaceutical partners.
For more information, visit www.centogene.com and follow us on
LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others,
negative economic and geopolitical conditions and instability and
volatility in the worldwide financial markets, possible changes in
current and proposed legislation, regulations and governmental
policies, pressures from increasing competition and consolidation
in our industry, the expense and uncertainty of regulatory
approval, including from the U.S. Food and Drug Administration, our
reliance on third parties and collaboration partners, including our
ability to manage growth and enter into new client relationships,
our dependency on the rare disease industry, our ability to manage
international expansion, our reliance on key personnel, our
reliance on intellectual property protection, fluctuations of our
operating results due to the effect of exchange rates, our ability
to streamline cash usage, our requirement for additional financing,
or other factors. For further information on the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to CENTOGENE’s business in general, see CENTOGENE’s risk
factors set forth in CENTOGENE’s Form 20-F filed on March 30, 2022,
with the Securities and Exchange Commission (the “SEC”) and
subsequent filings with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Media Contact:
CENTOGENE Ben Legg Corporate Communications
Press@centogene.com
Lennart Streibel Investor Relations
Investor.Relations@centogene.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Apr 2023 to Apr 2024